Home / Clinical Decision Support & Reference / Glytec Glucommander

Glytec Glucommander

by Glytec, LLC · Based in United States → — Stopping Preventable Harm. Backed by Over 20 Years of Proven Outcomes.

Critical Care Endocrinology Hospital Medicine

Website

Claim this tool

Is this the maker? Claim the company →

Leave this field empty

Correct company / maker

Company website (optional)

Anything else? (optional)

Contact glytec for pricing details.

Regulatory Status Disclosed

Overview

GlytecOne is a unified glycemic management platform that integrates clinical decision support, workflow automation, performance analytics, and enterprise population health intelligence. It connects care team members and hospital leaders with data and tools to deliver safer, more consistent glucose management across health systems. Glytec’s eGlycemic Management System (eGMS) centers on Glucommander, an FDA-cleared, cloud-based software that provides personalized insulin dosing recommendations for both IV and subcutaneous insulin therapy in hospitals and health systems. It helps hospitals standardize metabolic care, surface risk before it becomes harm, and prove measurable outcomes. GlytecOne also helps health plans close the metabolic care gap for inpatient and post-discharge to close Stars and HEDIS measure gaps for health plan members.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

FDA-cleared insulin dosing guidance (IV and SubQ)
Personalized insulin dosing recommendations
EHR integration (Epic, Cerner, Meditech, and others)
Clinical decision support and workflow automation
Real-time patient visibility and structured clinical review (Command Center)
Enterprise analytics, benchmarking, and eCQM-aligned reporting
Population health intelligence for glycemic management
Safety guardrails and alerts (e.g., glucose velocity warnings)
Automated data import and single sign-on
Support for complex conditions like DKA and HHS

Use Cases

Standardizing metabolic care in hospitals
Reducing severe hypoglycemia and hyperglycemia events
Decreasing hospital length of stay
Lowering 30-day readmission rates for patients with diabetes
Improving compliance with glycemic control quality measures (CMS eCQMs)
Optimizing insulin therapy across the continuum of care (inpatient to outpatient)

What Physicians Need to Know

Evidence Base (guidelines, literature scope)

Glytec Glucommander is an FDA-cleared, algorithm-driven insulin dosing software that replaces traditional sliding scale insulin therapy and paper protocols. [1, 19, 30] It is supported by over 100 peer-reviewed publications and 100 patents. [11] The system provides personalized insulin dosing recommendations based on real-time and historical patient data, learning each patient's insulin sensitivity. [1, 3] It aligns with guidelines from leading organizations like the American Diabetes Association (ADA) for inpatient glycemic management, advocating for safe IV insulin use in critically ill patients and basal-bolus therapy for non-ICU patients. [27, 34]

Clinical Validation Studies

Numerous studies validate Glucommander's safety and efficacy. [18] Hospitals using Glucommander have reported a reduction in severe hypoglycemia by up to 73% (and 99.8% reduction in severe hypoglycemia in some cases), a decrease in length of stay by up to 3.2 days, and lower 30-day readmission rates for patients with diabetes. [2, 19, 30] One study showed a 98% reduction in severe hypoglycemia (<70 mg/dL) at Grady Health System. [23, 25] In a study of DKA patients, Glucommander achieved equally rapid glycemic control and acidosis correction with less intravenous insulin and shorter PICU and hospital stays compared to manual infusion. [15] Another study demonstrated improved Time-in-Range (TIR) from 48.0% to 73.8% in Type 2 Diabetes patients using Glucommander with CGM data. [12] A multi-center retrospective study involving 1,750 DKA patients across 34 medical centers found optimal outcomes with a specific initial multiplier and glucose target range, with a total of 7.9% of patients experiencing hypoglycemia. [24]

Alert Fatigue Management

Glucommander helps reduce alert fatigue by providing data through predefined criteria, delivering meaningful information rather than generic notifications. [9] It includes safety features like glucose velocity warnings, alerting nurses to sudden drops in blood glucose to prevent hypoglycemia. [1, 6, 20] The system also dynamically adjusts the next blood glucose check based on patient values and trends. [1]

Override Rate Data

While specific override rate data is not explicitly provided, Glytec emphasizes that clinicians review and confirm all insulin dosing recommendations generated by Glucommander. [4, 9, 14, 21, 23] This indicates that the system provides decision support, but the final decision rests with the healthcare professional.

Drug Interaction Checking

Glucommander is designed to adjust insulin dosing recommendations based on changes in patient condition and medications. [20] While not explicitly detailed as a comprehensive drug interaction checker, it acknowledges the impact of other medications, such as steroids, on blood glucose levels. [20]

Differential Diagnosis Support

Glucommander is a specialized tool for glycemic management and insulin dosing, not a general diagnostic tool. [9] Its primary function is to provide personalized insulin recommendations for patients with hyperglycemia, including those with conditions like diabetic ketoacidosis and hyperosmolar hyperglycemic state. [6, 16, 32]

Guideline Update Frequency

Glytec's solutions are continuously updated, with the latest version of Glucommander (3.5.3.0) supporting Epic's latest Hyperspace client as of August 2023. [8] The company also references alignment with annual updates to guidelines such as the ADA Standards of Care in Diabetes. [27]

Clinical Workflow Integration

Glucommander is designed for seamless integration with existing EHR systems, including Epic, Cerner (Oracle Health), and Meditech, via bi-directional interoperability. [2, 7, 8, 11, 14, 32] This allows for automated import of patient information and lab results (ADT, LIS), single sign-on (SSO), and automated documentation of clinician-confirmed dosing decisions back into the EHR. [6, 7, 10, 14, 22] It provides a guided workflow, safety alerts, and surveillance, reducing manual data entry, charting time, and transcription errors. [5, 6, 7, 9, 22] GlucoView and GlucoSurveillance modules offer dashboards for patient glucose status, next BG check reminders, and identification of at-risk patients. [1, 3, 22]

Decision Audit Trail

GlytecOne includes built-in audit trails and documentation support, logging every dosing decision and pharmacist review. [4, 7, 14, 17, 21] This ensures that all glycemic management decisions are defensible and traceable, supporting medication safety reviews, Joint Commission preparation, and regulatory compliance. [4, 14, 21]

Physician Tip

Glucommander is an FDA-cleared, algorithm-driven tool that provides personalized insulin dosing recommendations for both IV and subcutaneous insulin therapy in adult and pediatric patients (ages 2 and above). [1, 4, 20, 32, 35] It is designed to reduce hypoglycemia and hyperglycemia, decrease length of stay, and lower readmission rates. [2, 5, 19, 30] Remember that while the software provides evidence-based recommendations, the final clinical decision and confirmation of dosing remain with the healthcare professional. [4, 9, 14, 21, 23] Leverage its seamless EHR integration to streamline workflows and reduce manual tasks, allowing more focus on patient care. [6, 7, 9, 22] Utilize the surveillance and analytics tools (GlucoSurveillance, GlucoView, GlucoMetrics) for proactive patient monitoring, care coordination, and performance tracking. [1, 3, 16, 22]

Glytec Glucommander offers robust bi-directional integration with major EHR systems, including Epic, Oracle Health (Cerner), and Meditech. [2, 7, 8, 11, 14, 32] This integration facilitates automated data exchange for patient demographics (ADT), lab results (LIS), insulin orders, and medication administration records (MAR), minimizing manual entry and transcription errors. [7, 10] Single sign-on (SSO) capability further enhances workflow efficiency. [6, 7] The platform is EHR-agnostic and can integrate with any EHR system. [10]

At a glance

Pricing Contact glytec for pricing details.

Deployment Cloud Based

Visit site

Details

Category	Clinical Decision Support & Reference, Endocrinology & Metabolic AI, Pharmacology & Dosing AI
Pricing	Contact glytec for pricing details. Glytec does not publicly disclose pricing information Hospitals can expect a significant return on investment (6-8x ROI) and average cost savings of over $10,000 per severe hypoglycemic event
Deployment	Cloud-based
Compliance
BAA Available	Unknown AI-estimated
HIPAA Compliant	Unknown AI-estimated
FDA Status	1 AI-estimated Glucommander is an FDA-cleared Class II Software as a Medical Device (SaMD) for glycemic management. It is indicated for use in adult and pediatric patients (ages 2-17 years) for both IV and subcutaneous insulin dosing.
Integrations
EHR	Not specified
Specialties	Critical Care, Endocrinology, Hospital Medicine

What the Web Says

Glytec Glucommander is a widely recognized software solution for glycemic management in healthcare settings, particularly for insulin dosing. Reviews highlight its effectiveness in improving patient outcomes, reducing hypoglycemia, and standardizing care across various hospital departments. While generally well-received for its clinical benefits, some users point to the learning curve and integration challenges as potential drawbacks.

Overall: Positive

Strengths

Significantly reduces hypoglycemia and hyperglycemia events
Improves patient safety and outcomes in glycemic control
Standardizes insulin dosing protocols across care settings
Reduces workload for nurses and clinicians by automating calculations
Supports both IV and subcutaneous insulin management
Provides data for quality improvement and compliance reporting

Limitations

Can have a steep learning curve for new users
Integration with existing EHR systems can be complex and time-consuming
Requires significant initial setup and training investment
Some users report occasional software glitches or performance issues
May require dedicated IT support for ongoing maintenance
Cost can be a barrier for smaller institutions

Based on reviews from: G2, Capterra, Reddit (various healthcare subreddits), Healthcare IT News, Physician reviews (various medical forums and publications), Glytec official website (for product information and case studies)

Last updated: 2026-06-23

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Glytec Glucommander

Clinical Value

Ease of Use

Integration

Support & Docs

Value for Money

Your Name *

Email *

Your Role

Specialty

Your Review * (min 50 characters)

No press coverage or publications on file yet. Know of some? Suggest an edit →

Videos

Product demos, reviews, and walkthroughs for Glytec Glucommander.

IntelliSource International Client Work: Glytec - Sentara, Webinar

IntelliSource International

View all on YouTube

Frequently Asked Questions

How does Glytec Glucommander integrate into existing clinical workflows and what are the typical steps for a physician to use it?

Glytec Glucommander is designed to integrate with electronic health records (EHRs) to streamline the management of insulin. Physicians typically input patient-up-to-date information, and the system provides individualized insulin dosing recommendations. The platform aims to reduce the burden of manual calculations and frequent blood glucose checks by offering proactive adjustments.

What evidence supports the efficacy and safety of Glytec Glucommander in various patient populations, particularly in terms of reducing hypoglycemia and hyperglycemia?

Clinical studies and real-world data have demonstrated Glytec Glucommander's effectiveness in maintaining glycemic control while minimizing the risk of hypoglycemia. The system's algorithm dynamically adjusts insulin doses based on patient response, which contributes to improved safety and tighter glucose management across diverse patient populations, including those in critical care and general medical-surgical units.

What are the primary limitations of Glytec Glucommander, and in which clinical scenarios might it not be the most appropriate solution for insulin management?

While highly effective, Glytec Glucommander may have limitations in specific scenarios, such as patients with extremely rare or complex metabolic conditions not accounted for in its algorithms. It also requires consistent and accurate data input for optimal performance. In situations where frequent and rapid changes in patient status make algorithmic predictions challenging, close clinical oversight remains crucial.

How does Glytec Glucommander compare to other insulin management software or protocols, and when might a physician choose it over an alternative?

Glytec Glucommander differentiates itself through its individualized, real-time algorithmic adjustments for both intravenous and subcutaneous insulin. Physicians might choose it over other solutions due to its proven track record in reducing glycemic variability and its ability to adapt to changing patient needs, which can lead to better outcomes and reduced nursing burden compared to traditional protocols.

What is the typical physician compliance rate with Glytec Glucommander recommendations, and what features are in place to encourage adherence and optimize patient outcomes?

Glytec Glucommander aims to foster high physician compliance through clear, evidence-based recommendations and seamless EHR integration. The system provides alerts and notifications to guide timely interventions, and its user-friendly interface is designed to build physician confidence in the suggested insulin adjustments, ultimately promoting consistent application of the protocol for improved patient safety and glycemic control.

What are the cost implications of implementing Glytec Glucommander for a healthcare institution, and what is the typical return on investment in terms of reduced complications and length of stay?

The cost of implementing Glytec Glucommander involves licensing fees and integration expenses, which can vary based on the size and complexity of the healthcare institution. However, studies often show a positive return on investment through reductions in hypoglycemia-related events, decreased lengths of hospital stay, and improved patient outcomes, leading to overall cost savings and enhanced quality of care.